Program
petosemtamab
Also written as “Petosemtamab”, “MCLA-158” and “MCLA-158 + Pembrolizumab”.
Its studies are mostly in Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Lung Neoplasms, led by Genmab.
Furthest: phase 3, since Jul 3, 20246 company-led studies, 5 open or runningNext primary completion: Jan 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genmab | 65 open or running | phase 3since Jul 3, 2024 | Apr 4, 2018 | Jan 2028phase 3 · NCT06525220 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 4, 2018First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT03526835 · 560 planned · United States, Belgium, France and more
- Jul 3, 20242 phase 3 studies in Squamous Cell Carcinoma of Head and NeckNCT06496178, NCT06525220
- Jan 16, 2026Phase 2 study in Lung NeoplasmsNCT07353957 · United States, Australia, France and more
- Jul 9, 2026Phase 3 study in Left-sided Colorectal CancerNCT07702032 · 960 planned · United States, Australia, Puerto Rico
- Aug 13, 2026Phase 3 study in Colorectal NeoplasmsNCT07775287 · 600 planned · United States, Puerto Rico
Ahead
- Jan 2028Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06525220
- Feb 2028Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06496178
- May 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT03526835
- Mar 30, 2029Primary completion: phase 3 study in Colorectal NeoplasmsNCT07775287
TargetBeta
“An immunoglobulin G1 (IgG1) bispecific antibody targeting both epidermal growth factor receptor (EGFR; HER1; ErbB1) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), ”NCIt, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07775287Colorectal Neoplasms · United States, Puerto Rico | 3 | Recruiting | Mar 30, 2029 | 600 |
| NCT07702032Left-sided Colorectal Cancer · United States, Australia, Puerto Rico | 3 | Recruiting | Jul 2029 | 960 |
| NCT07353957Lung Neoplasms · United States, Australia, France and more | 2 | Withdrawn | May 31, 2028 | 0 |
| NCT06525220Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 2028 | 699 |
| NCT06496178Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2028 | 621 |
| NCT03526835Colorectal Neoplasms · United States, Belgium, France and more | 2 | Recruiting | May 2028 | 560 |
How it is read
Names in the registry
- “Petosemtamab”, 4 entries
- “MCLA-158”, 1 entry
- “MCLA-158 + Pembrolizumab”, 1 entry
- “MCLA-158 + FOLFIRI”, 1 entry
- “MCLA-158 + FOLFOX”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.